We have 22,000 employees in 66 countries, including nearly 3,000 researchers developing drugs for the future. Servier is currently developing drug candidates for the treatment of oncological, cardiological, metabolic, neuropsychiatric and rheumatological diseases. Servier has offices in 5 continents, 148 countries. 100 million patients treated each day worldwide with Servier medicines. 5 major R&D areas – cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes.